Request Demo
Last update 15 Dec 2025
SHR-A1912
Last update 15 Dec 2025
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms SHR A1912, SHR-A1912, SHRA1912 |
Target |
Action inhibitors |
Mechanism CD79B inhibitors(B-cell antigen receptor complex-associated protein beta chain inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States) |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
5
Clinical Trials associated with SHR-A1912NCT06929624
A Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
CTR20251332
SHR-A1912联合利妥昔单抗+吉西他滨+奥沙利铂(R-GemOx)对比R-GemOx在复发难治弥漫大B细胞淋巴瘤中的随机、开放3期临床研究
[Translation] A randomized, open-label phase 3 clinical study of SHR-A1912 combined with rituximab + gemcitabine + oxaliplatin (R-GemOx) versus R-GemOx in relapsed or refractory diffuse large B-cell lymphoma
NCT06104553
A Phase Ib/II Study of SHR-A1912 Combined With Other Therapies in Patients With B-cell Non-Hodgkin 's Lymphoma
100 Clinical Results associated with SHR-A1912
Login to view more data
100 Translational Medicine associated with SHR-A1912
Login to view more data
100 Patents (Medical) associated with SHR-A1912
Login to view more data
100 Deals associated with SHR-A1912
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | Phase 3 | China | 24 Apr 2025 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | China | 24 Apr 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 41 | SHR-A1912 + R-GemOx | tkapxokkjt(hujthiofua) = cphxlcudmm qwamkewucg (mqymoyayao, 55.9 - 86.2) View more | Positive | 30 May 2025 | ||
Phase 1 | 49 | wsonhvhcqq(gnldyskupe) = jhdvfjfpxs kkksgqeoqr (sefwutsdzt, 39.8 - 71.5) | Positive | 24 May 2024 | |||
wsonhvhcqq(gnldyskupe) = gszureuxov kkksgqeoqr (sefwutsdzt, 39.8 - 71.5) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free